Psychiatr Serv 51:634-638, May 2000
© 2000 American Psychiatric Association
Changes in Use of Valproate and Other Mood Stabilizers for Patients With Schizophrenia From 1994 to 1998
Leslie Citrome, M.D., M.P.H.,
Jerome Levine, M.D. and
Baerbel Allingham, M.S.
OBJECTIVE: The study describes changes over time in the adjunctive use of valproate and other mood stabilizers—lithium, carbamazepine, and gabapentin—among hospitalized psychiatric patients with a diagnosis of schizophrenia. METHODS: For each calendar year from 1994 through 1998, data were drawn from a database containing clinical and drug prescription information for every inpatient in the adult civil facilities of the New York State Office of Mental Health. RESULTS: In 1994 a total of 26.2 percent of inpatients diagnosed as having schizophrenia received a mood stabilizer, compared with 43.4 percent in 1998. In 1994 lithium was the most commonly prescribed mood stabilizer, for 13.2 percent of patients, followed by valproate, for 12.3 percent. In 1998 valproate was the most commonly prescribed, for 35 percent of patients, followed by lithium, for 11.3 percent. On average, patients received valproate for about two-thirds of their hospital stay, at a mean dose of 1,520 mg per day. CONCLUSIONS: The adjunctive use of valproate nearly tripled from 1994 to 1998 among patients with a diagnosis of schizophrenia. Valproate has become the most commonly prescribed mood stabilizer for this population, despite the paucity of evidence in the literature for efficacy in this use. Controlled clinical trials are needed to examine the adjunctive use of mood stabilizers, in particular valproate, among patients with schizophrenia.
This article has been cited by other articles:
|
|
|
|
 
C. H. Large
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
J Psychopharmacol,
May 1, 2007;
21(3):
283 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. CITROME, A. JAFFE, and J. LEVINE
Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients
Am J Psychiatry,
March 1, 2005;
162(3):
631 - 631.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, R. Josiassen, N. Bark, D. E. Salazar, and S. Mallikaarjun
Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate
J. Clin. Pharmacol.,
January 1, 2005;
45(1):
89 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, B. Allingham, and J. Robinson
Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients
Psychiatr Serv,
September 1, 2004;
55(9):
1006 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, D. E. Casey, D. G. Daniel, P. Wozniak, L. D. Kochan, and K. A. Tracy
Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone
Psychiatr Serv,
March 1, 2004;
55(3):
290 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, and B. Allingham
Datapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001
Psychiatr Serv,
October 1, 2002;
53(10):
1212 - 1212.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chen, R. P. Sharma, R. H. Costa, E. Costa, and D. R. Grayson
On the epigenetic regulation of the human reelin promoter
Nucleic Acids Res.,
July 1, 2002;
30(13):
2930 - 2939.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
